Recent

% | $
Quotes you view appear here for quick access.

Prana Biotechnology Limited Message Board

kadaicher1 352 posts  |  Last Activity: 1 hour 48 minutes ago Member since: Jan 23, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    How to Value Biotech Stocks

    by copper725 2 hours 16 minutes ago
    kadaicher1 kadaicher1 1 hour 48 minutes ago Flag

    You copper, you don't know how to value biotech stocks. You think there have to be earnings. With a trial running I think this stock is worth at least 300% over this price. Maybe much more. Now you need to judge when this is going to happen. You think there is no value when the co is on the cusp of a phase3, with good phase2 results to base it on.
    They have told the shareholders what is going on. You can't be helped. Data will be complete early this year. There is no way I want bashers like you to have the exact date. I was very unhappy with the lack of detail of the original PCH announcement, but I am happy with the level of info to this point. Gives me a chance to accumulate more before the hold is lifted or the EU trial starts.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 3 hours ago Flag

    One is for chorea and the other drug is for cognition. Interesting the tetrabenazine trial was only 12 weeks. Also interesting it was the HSG who brought it through to market.
    Prana does not own any of the examples, but I guess you are just grasping for a negative here, and there are not any.
    "Unproven" , sure, but it is nice to know it has significantly improved exec function in both AD and HD. To me the odds are very good the Reach2HD results will be replicated in the P3.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 3 hours ago Flag

    Why are you posting here if you have no idea of how to value a biotech. FYI PBT434 is also waiting on this safety package which is about to be delivered. PBT434 has possible utility in several orphans and Parkinson's. With 434 they can go for the blockbuster or the orphans. You are correct that a preclinical candidate generally adds no value to the SP but with PBT434 ready to go to the clinic, that is another value point to be added near term. A year between trials is not unusual for small biotechs, no matter how much you try to make it sound catastrophic. At this point what is important to the SP is just starting the trials.

    Sentiment: Strong Buy

  • Reply to

    Any news today?

    by copper725 Feb 6, 2016 7:08 AM
    kadaicher1 kadaicher1 3 hours ago Flag

    You have no idea of my trading, so don't pretend you do. All I am saying is at 50c this is a snap. Prana did say the data would be complete early this year and this is early this year. Why would you be telling people to sell at this point?
    Remember this is going into a phase3 trial for the lead drug of a new class of drugs for neurodegeneration. You are trying to construct a bleak outlook when it is the opposite. This trial initiation is what they have been working towards for a decade and a half.

    Sentiment: Strong Buy

  • Reply to

    Any news today?

    by copper725 Feb 6, 2016 7:08 AM
    kadaicher1 kadaicher1 4 hours ago Flag

    Sure, but you don't have the probability of an easy 10 bagger with GE. I thought $1.60 was pretty cheap before the PCH bombshell. This was misrepresented somewhat as a worldwide hold, which it is not. It put Prana in a position where they had to make a very strong safety package before proceeding with any of the regulators, but the PCH only applies in the USA. With 8 human clinical trials already completed in that data package I think the FDA will lift the hold.

    Sentiment: Strong Buy

  • Reply to

    Any news today?

    by copper725 Feb 6, 2016 7:08 AM
    kadaicher1 kadaicher1 5 hours ago Flag

    Just look at the chart copper. You will see it there when it happens. That is why I am still accumulating.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 5 hours ago Flag

    Of course the difference is actually that those companies have a single orphan drug approved. What this thread illustrates is the potential value of Prana in the same position, You are correct Prana are in a class of their own, and that class of drugs has potential utility in dozens of conditions.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 5 hours ago Flag

    And here is a 12 week trial which led to approval in another orphan, also executed by HSG.
    Neurology. 2006 Feb 14;66(3):366-72.
    Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial.
    Huntington Study Group.
    Abstract
    BACKGROUND:
    Tetrabenazine (TBZ) selectively depletes central monoamines by reversibly binding to the type 2 vesicular monoamine transporter. Open-label reports indicate TBZ is effective in treating chorea.
    OBJECTIVE:
    To examine the safety, efficacy, and dose tolerability of TBZ for treating chorea in Huntington disease (HD).
    METHODS:
    The authors randomized 84 ambulatory patients with HD to receive TBZ (n = 54) or placebo (n = 30) for 12 weeks. TBZ was increased over 7 weeks up to a maximum of 100 mg/day or until the desired antichoreic effect occurred or intolerable adverse effects supervened. The primary outcome was the change from baseline in the chorea score of the Unified Huntington's Disease Rating Scale (UHDRS) RESULTS: TBZ treatment resulted in a reduction of 5.0 units in chorea severity compared with a reduction of 1.5 units on placebo treatment (adjusted mean effect size = -3.5 +/- 0.8 UHDRS units [mean +/- SE]; 95% CI: -5.2, -1.9; p 0.0001). There was also a significant benefit on ratings of clinical global improvement. There were five study withdrawals in the TBZ group and five serious adverse events (SAEs) in four subjects (drowning suicide, complicated fall, restlessness/suicidal ideation, and breast cancer) compared with one withdrawal and no SAEs in the placebo group.
    CONCLUSION:
    Tetrabenazine (TBZ), at adjusted dosages of up to 100 mg/day, effectively lessens chorea in ambulatory patients with Huntington disease. TBZ should be dosed individually based on ongoing assessment of possible adverse side effects.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Feb 8, 2016 5:36 AM Flag

    My take is that Kempler will be speaking about the data package completed and a phase3 trial ramp up.
    We already know Prana has been investigating the utility of PBT434 in several Parkinsonian and tauopathy orphan indications, so I would be amazed if he was not speaking about the PBT434 orphan targets.
    Is it PBT519 you are thinking about? I am not sure if the brain cancer indication is an orphan indication.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Feb 7, 2016 12:21 PM Flag

    I see they are in the pitch and partner session. Maybe looking for a partner for the Parkinsonian orphans.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Feb 7, 2016 12:12 PM Flag

    Nice to see Prana getting out there. I guess Kempler expects to have something to market by that time. Prana have many orphan candidates in the pipeline.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Feb 7, 2016 12:07 PM Flag

    Just being a little simplistic there colton. I am accumulating, but then again so probably are you.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Feb 7, 2016 12:04 PM Flag

    Sorry I can't post replies to copper under his posts because the slimeball deletes his posts and reposts to lose the reply.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Feb 7, 2016 12:02 PM Flag

    That quote was from the annual report and once more for copper who loses his comprehension skills at will.
    " the combined FDA non-clinical, clinical pharmacology and safety analysis package will be used in submissions to European and other regulators in support of our global development plans and prospective marketing approvals."
    Fact is the trial will go ahead as soon as the data package is ready. Will it be in the USA, who cares, not me, except I hope US patients get the opportunity. Maybe with patients facing conversion to symptomatic NOW, the FDA will still be more interested in dog brains, but I think the FDA will want to proceed with P3 trials after telling patients and advocates at the last conference they were not holding up any HD drugs.
    You are correct copper that control is now in Prana's hands, but there is the issue of the FDA PCH in the US only.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Feb 7, 2016 8:25 AM Flag

    What you need to understand is that Prana have run screens over all those candidates and have identified the most potent so far in PD, AD and brain cancer. There has also been work done for macular degeneration, patents filed 2007. What door is locked. The FDA have just asked for a data package which is about complete.
    ". Based on the emerging strong safety profile for PBT2, we are preparing a robust safety monitoring plan for future trials in HD. These plans will be submitted to the FDA as part of our response and the combined FDA non-clinical, clinical pharmacology and safety analysis package will be used in submissions to European and other regulators in support of our global development plans and prospective marketing approvals. "
    The door is not locked, just a temporary obstruction in the USA.

    Sentiment: Strong Buy

  • Reply to

    Rate the odds of the PCH being lifted for 250mg

    by kadaicher1 Jan 14, 2016 1:26 PM
    kadaicher1 kadaicher1 Jan 29, 2016 4:11 AM Flag

    So you are saying the trial will go ahead in the EU/AUS without the USA on board. That would not be the first time that happened. It is what Roche is doing with their HD effort, also in Canada. That said I think you are just a run of the mill lying short trader unless you can expand on how you can guarantee it.
    I remind you the trial start is dependent on Prana completing the safety data package, not the PCH.

    Sentiment: Strong Buy

  • Reply to

    REALITY - anyone?

    by copper725 Jan 25, 2016 8:01 AM
    kadaicher1 kadaicher1 Jan 28, 2016 7:16 AM Flag

    I have not noticed much truth coming from copper. Just meaningless generalities. Buying.
    Some investors understand that there are bound to be problems at the cutting edge of the science going against diseases which no one, even pharmas with 10B R&D budgets, have been unable to even scratch. In this case I believe it is important to look to the scientific leaders in the field, rather than just the direction of pharma's who have wrong almost 100% of the time.
    I agree don't listen to message board posts except to find info to research yourself. In Huntington's disease an organization like the Huntington's Study Group, a worldwide group of volunteer doctors dedicated to finding a cure or effective treatment for HD would be a trusted source of opinion on PBT2, having run the Reach2HD trial. They have in depth understanding of PBT2 and only have patients welfare in mind.

    Sentiment: Strong Buy

  • Reply to

    Rate the odds of the PCH being lifted for 250mg

    by kadaicher1 Jan 14, 2016 1:26 PM
    kadaicher1 kadaicher1 Jan 28, 2016 5:21 AM Flag

    Copper that was the first human trial of PBT2 in HD. Primary endpoint was safety which they nailed. The rest was very much exploratory and to demonstrate significant results in any measure is fantastic. To replicate the TMTB results from Euro, demonstrating utility across both neurodegenerative diseases tested with the same drug is what some expected, but it should eliminate all doubt.

    Sentiment: Strong Buy

  • Reply to

    Rate the odds of the PCH being lifted for 250mg

    by kadaicher1 Jan 14, 2016 1:26 PM
    kadaicher1 kadaicher1 Jan 27, 2016 12:26 AM Flag

    Regarding the word fluency test gains demonstrated in Euro. Fluency is the other most critical measure in conversion to dementia.
    [ In types of dementia other than AD, impairment in TMTB, psychomotor speed and verbal fluency even dominate the clinical profile of patients, for example, in VaD and MD [49] as well as in patients with vascular white matter lesions. Impaired verbal fluency [19,50] and reduced speed of processing on the TMT [51] may be caused by subcortical or frontal lesions, the same functions are known to be affected in patients with small vessel disease, which is related to progressive cognitive impairment and a considerable risk of developing dementia ]

    Sentiment: Strong Buy

  • Reply to

    Rate the odds of the PCH being lifted for 250mg

    by kadaicher1 Jan 14, 2016 1:26 PM
    kadaicher1 kadaicher1 Jan 26, 2016 3:26 PM Flag

    It is because it is the most difficult of the tests copper, and where you would expect improvements to show. It is also the measure best able to reveal cognitive reserve just before and after onset. That is very critical stage of the disease.

    Sentiment: Strong Buy

PRAN
0.5002Feb 8 3:58 PMEST